Nektar officer plans sale of 186 company shares

NEKTAR THERAPEUTICS (NKTR) had a Form 144 notice filed in connection with planned sales of its common stock by officer Jonathan Zalevsky.

Rhea-AI Filing Summary

NEKTAR THERAPEUTICS (NKTR) had a Form 144 notice filed in connection with planned sales of its common stock by officer Jonathan Zalevsky. The notice covers a proposed sale of 186 shares of NKTR common stock, with an aggregate market value of $13,387.96 as of August 18, 2026, to be sold on NASDAQ. The securities to be sold were acquired through restricted stock vesting on August 14, 2026, as compensation from the issuer. The filer also reports that the planned sale includes shares needed to cover a related tax obligation, and notes a prior sale of 199 shares for $13,035.36 on May 19, 2026.

Key Figures

Shares planned for sale: 186 shares Aggregate market value of planned sale: $13,387.96 Security identifier: 34142994 +4 more

7 metrics

Shares planned for sale 186 shares Common stock covered by the Form 144 notice

Aggregate market value of planned sale $13,387.96 Value for 186 NKTR shares as of August 18, 2026

Security identifier 34142994 Numeric identifier listed with the common stock entry

Prior shares sold 199 shares Common stock sold on May 19, 2026

Aggregate amount of prior sale $13,035.36 Total for 199 NKTR shares sold on May 19, 2026

Date of notice 08/18/2026 Date the Form 144 notice was signed and filed

Acquisition date of vested stock 08/14/2026 Date of restricted stock vesting underlying the planned sale

Key Terms

Form 144, Rule 144, Restricted Stock Vesting, vested equity award

4 terms

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 08/14/2026 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

vested equity award financial

"resulting from the settlement of a vested equity award distribution."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing mean for NEKTAR THERAPEUTICS (NKTR)?

The Form 144 for NEKTAR THERAPEUTICS (NKTR) discloses an officer’s planned sale of 186 shares of common stock. It is a regulatory notice for potential sales under Rule 144, not a company-level financing transaction.

How many NKTR shares are covered by Jonathan Zalevsky’s planned sale?

The notice covers a planned sale of 186 shares of NEKTAR THERAPEUTICS common stock. These shares relate to restricted stock vesting on August 14, 2026, and part of the sale is intended to cover associated tax obligations.

What is the reported value of the NKTR shares in the new Form 144?

The Form 144 lists an aggregate market value of $13,387.96 for the 186 shares of NKTR common stock. This value is tied to the planned sale on NASDAQ as of the notice date of August 18, 2026.

What prior NKTR stock sales by Jonathan Zalevsky are disclosed?

The filing reports that on May 19, 2026, Jonathan Zalevsky sold 199 shares of NEKTAR THERAPEUTICS common stock for an aggregate amount of $13,035.36. This transaction occurred within the three months preceding the new Form 144 notice.

How were the NKTR shares to be sold originally acquired by Jonathan Zalevsky?

The shares were acquired through restricted stock vesting on August 14, 2026 as compensation from NEKTAR THERAPEUTICS. The Form 144 notes the transaction type as “Restricted Stock Vesting” with the nature of acquisition described as Compensation.

Why does the Form 144 mention taxes related to NKTR stock?

The remarks specify that the sale includes an amount necessary to cover a tax obligation arising from settlement of a vested equity award. This means part of the NKTR share sale is intended to satisfy tax liabilities tied to the vested compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/18/2026 - 03:57 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001789857
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	NEKTAR THERAPEUTICS
SEC File Number	000-24006
Address of Issuer	455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CALIFORNIA 94158
Phone	4154825300
Name of Person for Whose Account the Securities are To Be Sold	Zalevsky Jonathan
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	186	13387.96	34142994	08/18/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/14/2026	Restricted Stock Vesting	Issuer			186	08/14/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jonathan Zalevsky 455 Mission Bay Boulevard South San Francisco CA 94158	Common	05/19/2026	199	13035.36

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	08/18/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Jonathan Zalevsky.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)